Liese Barbier

622 total citations
36 papers, 362 citations indexed

About

Liese Barbier is a scholar working on Economics and Econometrics, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Liese Barbier has authored 36 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Economics and Econometrics, 20 papers in Immunology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Liese Barbier's work include Pharmaceutical Economics and Policy (21 papers), Biosimilars and Bioanalytical Methods (20 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Liese Barbier is often cited by papers focused on Pharmaceutical Economics and Policy (21 papers), Biosimilars and Bioanalytical Methods (20 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). Liese Barbier collaborates with scholars based in Belgium, Netherlands and United States. Liese Barbier's co-authors include Arnold G. Vulto, Isabelle Huys, Steven Simoens, Paul Declerck, Hans C. Ebbers, Patrick Neven, Barbara Claus, Pascal Borry, Philippe Van Wilder and Rosanne Janssens and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Reviews Drug Discovery and British Journal of Cancer.

In The Last Decade

Liese Barbier

32 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liese Barbier Belgium 9 288 224 119 54 41 36 362
Evelien Moorkens Belgium 10 258 0.9× 218 1.0× 73 0.6× 27 0.5× 51 1.2× 17 360
Niklas Ekman Finland 6 320 1.1× 146 0.7× 105 0.9× 90 1.7× 56 1.4× 9 357
Michael Muenzberg United States 10 357 1.2× 191 0.9× 144 1.2× 203 3.8× 40 1.0× 16 516
Gabriele Reichmann Germany 5 294 1.0× 112 0.5× 85 0.7× 108 2.0× 62 1.5× 5 351
Ena Singh United States 7 235 0.8× 119 0.5× 65 0.5× 41 0.8× 47 1.1× 7 323
Jolanta Węgłowska Poland 6 336 1.2× 122 0.5× 109 0.9× 38 0.7× 27 0.7× 16 437
Вячеслав Миколайович Ждан Ukraine 8 251 0.9× 102 0.5× 111 0.9× 30 0.6× 44 1.1× 74 379
Hans C. Ebbers Netherlands 14 514 1.8× 288 1.3× 196 1.6× 70 1.3× 89 2.2× 31 645
Johann Poetzl United Kingdom 8 299 1.0× 123 0.5× 128 1.1× 36 0.7× 46 1.1× 15 337
Heike Woehling Germany 9 300 1.0× 142 0.6× 140 1.2× 27 0.5× 34 0.8× 16 377

Countries citing papers authored by Liese Barbier

Since Specialization
Citations

This map shows the geographic impact of Liese Barbier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liese Barbier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liese Barbier more than expected).

Fields of papers citing papers by Liese Barbier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liese Barbier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liese Barbier. The network helps show where Liese Barbier may publish in the future.

Co-authorship network of co-authors of Liese Barbier

This figure shows the co-authorship network connecting the top 25 collaborators of Liese Barbier. A scholar is included among the top collaborators of Liese Barbier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liese Barbier. Liese Barbier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Simoens, Steven, Walter Van Dyck, Rosanne Janssens, Liese Barbier, & Jeroen Luyten. (2025). Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health Consequences. Applied Health Economics and Health Policy. 23(4). 613–624. 1 indexed citations
4.
Outtier, An, Rosanne Janssens, Liese Barbier, et al.. (2024). Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. United European Gastroenterology Journal. 13(4). 542–551. 2 indexed citations
5.
Barbier, Liese, Walter Droogné, Peter Sinnaeve, et al.. (2024). Heart Failure Patients' Perspectives on Treatment Outcomes and Unmet Medical Needs: A Qualitative Preference Study. ESC Heart Failure. 11(5). 3075–3084. 1 indexed citations
6.
Inotai, András, et al.. (2024). Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report. Value in Health. 27(5). 543–551. 1 indexed citations
7.
Broekmans, J. F., Rosanne Janssens, Liese Barbier, et al.. (2024). Needs Examination, Evaluation and Dissemination (NEED): applicability to rare diseases. Lirias (KU Leuven). 1 indexed citations
8.
Barbier, Liese, et al.. (2024). Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative. SHILAP Revista de lepidopterología. 12(3). 144–157. 4 indexed citations
9.
Borry, Pascal, et al.. (2023). Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study. BMC Health Services Research. 23(1). 181–181. 5 indexed citations
10.
11.
Janssens, Rosanne, Liese Barbier, Irina Cleemput, et al.. (2023). How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action. Frontiers in Pharmacology. 14. 1192770–1192770. 5 indexed citations
12.
Geerts, David, et al.. (2023). Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study. Journal of Medical Internet Research. 25. e46306–e46306. 1 indexed citations
13.
Zimmeren, Esther van, Timo Minssen, Walter Van Dyck, et al.. (2022). Compulsory licensing for expensive medicines. 1 indexed citations
14.
Simoens, Steven, Liese Barbier, Rosanne Janssens, et al.. (2022). How to balance valuable innovation with affordable access to medicines in Belgium?. Frontiers in Pharmacology. 13. 960701–960701. 7 indexed citations
15.
Zimmeren, Esther van, Timo Minssen, Walter Van Dyck, et al.. (2022). Compulsory licensing for expensive medicines. 1 indexed citations
16.
Barbier, Liese, et al.. (2022). Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine. 9. 820755–820755. 21 indexed citations
17.
Barbier, Liese, Steven Simoens, Paul Declerck, Arnold G. Vulto, & Isabelle Huys. (2022). Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. Frontiers in Pharmacology. 13. 821616–821616. 7 indexed citations
18.
Arnet, Isabelle, Anna Birna Almarsdóttir, Liese Barbier, et al.. (2021). Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. SHILAP Revista de lepidopterología. 4. 100084–100084. 4 indexed citations
19.
Barbier, Liese, Steven Simoens, Arnold G. Vulto, & Isabelle Huys. (2020). European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice. BioDrugs. 34(6). 797–808. 33 indexed citations
20.
Barbier, Liese, Hans C. Ebbers, Steven Simoens, et al.. (2018). PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS: A SYSTEMATIC REVIEW. Value in Health. 21. S309–S309. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evelien Moorkens Breakdown of academic impact, for papers by Niklas Ekman Breakdown of academic impact, for papers by Michael Muenzberg Breakdown of academic impact, for papers by Gabriele Reichmann Breakdown of academic impact, for papers by Ena Singh Breakdown of academic impact, for papers by Jolanta Węgłowska Breakdown of academic impact, for papers by Вячеслав Миколайович Ждан Breakdown of academic impact, for papers by Hans C. Ebbers Breakdown of academic impact, for papers by Johann Poetzl Breakdown of academic impact, for papers by Heike Woehling
Rankless by CCL
2026